Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 17.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,388 shares of the biopharmaceutical company’s stock after purchasing an additional 12,431 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.09% of Xenon Pharmaceuticals worth $4,965,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in XENE. Avoro Capital Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 0.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after buying an additional 24,444 shares during the period. Janus Henderson Group PLC raised its position in shares of Xenon Pharmaceuticals by 3.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock worth $183,110,000 after buying an additional 140,149 shares during the period. Wellington Management Group LLP boosted its holdings in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares during the last quarter. Capital International Investors boosted its holdings in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after acquiring an additional 233,466 shares during the last quarter. Finally, Commodore Capital LP raised its holdings in shares of Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after purchasing an additional 700,000 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

XENE has been the topic of a number of recent research reports. Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, March 16th. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, April 8th. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Finally, JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $60.96 on Monday. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $63.95. The business has a 50 day moving average price of $55.01 and a two-hundred day moving average price of $50.31. The firm has a market cap of $5.89 billion, a PE ratio of -12.97 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same period last year, the business earned ($0.83) earnings per share. On average, analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.